P. Hudson
Board of Directors
Novartis
France
Biography
Paul Hudson has been CEO of Novartis Pharmaceuticals since July 1, 2016. He is a member of the Executive Committee of Novartis. Mr. Hudson joined Novartis from AstraZeneca, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before AstraZeneca, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK. Paul Hudson has been CEO of Novartis Pharmaceuticals since July 1, 2016. He is a member of the Executive Committee of Novartis. Mr. Hudson joined Novartis from AstraZeneca, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before AstraZeneca, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.
Research Interest
Pharmaceuticals